Filing Flows › Comparisons › OCGN vs SCTX
Ocugen vs Scribe Therapeutics: OCGN and SCTX compared
Ocugen is the larger company: $2.0M of revenue in its latest quarter (Q3 2026) against $1.9M for Scribe Therapeutics (Q2 2026). Ocugen is growing faster (+11% against -61% a year earlier). Scribe Therapeutics is more profitable, with an operating margin of -489.8% against -909.9%.
Where the money goes: OCGN and SCTX
Ocugen (OCGN) · Q3 2026
Ocugen, Q3 2026: revenue $2.0M (+11% year over year), operating margin -909.9%, net loss $3.6M, operating cash flow −$15.7M. The chart follows the revenue to costs, profit and cash.
Scribe Therapeutics (SCTX) · Q2 2026
Scribe Therapeutics, Q2 2026: revenue $1.9M (-61% year over year), operating margin -489.8%, net loss $6.5M. The chart follows the revenue to costs, profit and cash.
| Ocugen (OCGN) | Scribe Therapeutics (SCTX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $2.0M | $1.9M |
| Revenue growth, Y/Y | +11% | -61% |
| Operating margin | -909.9% | -489.8% |
| Net earnings | −$3.6M | −$6.5M |
| Net margin | -184.4% | -337.7% |
| Operating cash flow | −$15.7M | — |
Questions
Which is bigger, Ocugen or Scribe Therapeutics?
Ocugen is the larger company: $2.0M of revenue in its latest quarter (Q3 2026) against $1.9M for Scribe Therapeutics (Q2 2026).
Is Ocugen or Scribe Therapeutics growing faster?
Ocugen is growing faster (+11% against -61% a year earlier).
Which is more profitable, Ocugen or Scribe Therapeutics?
Scribe Therapeutics is more profitable, with an operating margin of -489.8% against -909.9%.
More: Ocugen earnings · how Ocugen makes money · Scribe Therapeutics earnings · how Scribe Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Sep 2, 2026). Fiscal quarters can end on different dates. Not investment advice.